We found that post-treatment samples exhibit resistance to BRAF/MEK inhibition, which is accompanied by elevated expression of markers associated with cancer stem cells, differentiation, and chemo- and radiation-therapy resistance, including CD133, in the post-treatment tumor (3). The gene discussed is BRAF; the disease is neoplasm.